Role of ferroptosis in bacterial keratitis

Ophthalmology Times EuropeOphthalmology Times Europe May 2024
Volume 20
Issue 4
Pages: 13

Inhibiting ferroptosis could be crucial to reducing inflammation

Multicolor bacteria under a microscope. Image credit: ©Ilja –

The study results provide “a potential target for innovative therapeutic strategies for bacterial keratitis." Image credit: ©Ilja –

Ferroptosis is a form of cell death that depends on the presence of iron in the cells. Chinese investigators, led by first author Qiankun Chen, MD, recently reported identifying that ferroptosis “plays a crucial role in the pathogenesis of bacterial keratitis,” and inhibiting ferroptosis is promising to reduce inflammation and corneal scarring, and enhance the disease prognosis.1

Dr Chen is from the Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing, China.

Bacterial keratitis (BK) is a vision-threatening infection that can result in severe inflammation and corneal scarring and may lead to vision loss.

Dr Chen and colleagues explained, “The hallmark biochemical features of ferroptosis include the accumulation of iron, comprising both ferrous (Fe2+) and ferric (Fe3+) forms, and lipid peroxidation, resulting in the generation of reactive oxygen species (ROS) that induces cell death with an inflammatory component.“2 In their study, the research team set out to evaluate ferroptosis-related gene expression using transcriptome analysis in human corneas with BK (Pseudomonas aeruginosa) and normal donor corneas.

Next, mouse models of P. aeruginosa keratitis and corneal stromal stem cells were validated. The mice were treated with levofloxacin (LEV) or levofloxacin combined with ferrostatin-1 (LEV+Fer-1). The corneal stromal stem cells were treated with lipopolysaccharide (LPS) or LPS combined with Fer-1. Reverse transcriptase polymerase chain reaction, immunostaining, and Western blot were performed to evaluate the mouse RNA for anti-inflammatory cytokines, α-smooth muscle actin (α-SMA) and ferroptosis-related regulators. Iron and ROS were measured, the authors recounted.

The authors reported, “Transcriptome analysis revealed significant alterations in ferroptosis-related genes in human corneas with bacterial keratitis.”

The mouse models treated with LEV+Fer-1 showed reduced inflammatory cytokines, decreased corneal scarring and α-SMA expression, and lower Fe3+ compared with the BK and LEV groups. The LEV+Fer-1 group had markedly elevated glutathione peroxidase 4 (GPX4), a regulator of ferroptosis, and solute carrier family 7 member 11 (SLC7A11), an amino acid transporter that supports glutathione synthesis, in contrast with the BK and LEV group. In vitro, Fer-1 restored the changes in ROS, Fe2+, GPX4 and SLC7A11 induced by LPS in corneal stromal stem cells.

“Ferroptosis plays a crucial role in the pathogenesis of BK,” Dr Chen and colleagues reported. By inhibiting ferroptosis, they believe that inflammation and corneal scarring can be reduced and ultimately the prognosis of BK can be enhanced.

The investigators also pointed out that the results provide “a potential target for innovative therapeutic strategies for bacterial keratitis, which holds immense potential to transform the treatment of the infection.”


1. Chen Q, Wang L, Wei Y, et al. Ferroptosis as a potential therapeutic target for reducing inflammation and corneal scarring in bacterial keratitis. Invest Ophthalmol Vis Sci. 2024;65:29. doi:10.1167/iovs.65.2.29
2. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021; 31:107-125.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.